Search results
Results from the WOW.Com Content Network
How a new FDA-approved drug can — and can’t — help people with Alzheimer’s December 25, 2024 at 10:08 AM If you have a loved one with Alzheimer’s disease, you may have read about a newly ...
The approval of aducanumab, despite the lack of evidence to support its therapeutic effects, led to controversy about the FDA’s approval process and a reluctance to prescribe the drug.
Former FDA Commissioner Dr. Peggy Hamburg and NBC's Dr. John Torres join Andrea Mitchell with their analysis of the FDA's approving a new Alzheimer's drug for the first time since 2003, and why ...
An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients ...
The medication has shown some promise at addressing what may be an underlying cause of the disease, but its ability to slow or reverse cognitive decline remains unproven.
On Monday, the US Food and Drug Administration granted approval to a keenly-watched Alzheimer’s drug, aducanumab, developed by the drugmaker Biogen. Aducanumab, which will be marketed as Aduhelm ...
Image Provided By Unsplash In a controversial move this past June, the FDA approved Aduhelm™ as a treatment for Alzheimer’s disease. The controversy stems from the questionable efficacy and ...
This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. On Friday, Jan. 6, 2023, U.S. health officials approved Leqembi, a new Alzheimer ...